Florida Infusion presents: 
Inside the Pipeline 
Today's news, tomorrow's opportunties. 
In This Issue
 
Welcome
 
Around the Office
 
Inventory Matters
 
Quick Links
Oncology Associates
 
Recent Manufacturer
Price Increases to WAC
Aloxi 3.1%, Alimta 1.6%, Gemzar 2.3%, Doxil 2%, Taxotere 1.75%, Emend 3%, Boniva 2%, Cathflo Activase 3%, and Activase 3% 
Do we have your email address?
 
Join our list now.
 
Spotlight on Customer Service
Debbie Scott
Account Manager
July/2010

Dear Healthcare Professional,

 

It is an understatement to say that things are moving faster than ever in health care. And no one knows that better than you. Keeping your practice financially healthy and staying on top of what's happening in the pharmaceutical industry is also more difficult and time consuming than ever. As the supplier of your practice's biggest expense and trading partner to big pharma and group purchasing organizations like Oncology Associates, we want to do everything we can to keep you abreast of important developments that affect your practice. That's why were are please to introduce the first installment of our new e-newsletter, Inside the Pipeline to you this month.

 

Inside The Pipeline will bring you regular features focusing on big pharma, new products soon to be launched, products in late stage trials, mergers and acquisitions, new contract pricing and, did I mention, price increases. We'll also try to keep you updated on important manufacturer back-orders and releases, allocations, and recalls.   

 
We'll give you a personal look at some of the people who serve you on a regular basis and highlight healthcare professionals from around the country. 
 

We hope you will be pleased and ask for your comments and suggestions on how we can make Inside the Pipeline more useful.

 
Tom Magoulis
Vice President
Around the Office
 
On 07/13/2010, CMS lowered the bar for providers who are concerned about qualifying for federal incentive payments linked to the implementation of Electronic Health Records. The guidelines will apply in 2011 and 2012 as the transition to EHR's is instituted. Rather than instituting technology for technology's sake, the original guidelines aimed to set standards thought to impel providers to improve patient care. However, public input has led CMS to relax the standards to qualify for the incentive from 75% e-prescribing to 40% e-prescribing and reduced the number of benchmarks from 25 to 14. 
 
With the "doc fix" For Medicare payments now only extended to this November, it can only put further pressure on physician offices who have seen their payments held, reduced and now reinstated, as they contemplate the costs associated with moving to Electronic Health records.
 
Let us know what you think. 
 
Peter Maloney
Operations Manager
Inventory Matters
Florida Infusion makes every effort to supply you with all of your inventory needs by adding new product releases and expanding our inventory with alternative generics.
 

New product releases include Dactinomycin 500mcg/2ml (Bedford), Jevtana  (Sanofi),  Istodax 10mg vial kit (Celgene).

 

Recently added generic alternatives are products such as Methylprednisolone Acetate 40mg/ml 10ml  (Sandoz), Methylprednisolone Acetate 80mg/ml 5ml (Sandoz), Betamethasone Sod/Betamethasone Acetate 30mg/5ml (American Regent), and an innovative Administration Set manufactured by Truecare Biomedix (INF004) 100" non-Dehp, flow regulator, .22 micron filter Y-site 40/case.

 

We are pleased to have back in stock Vinblastine 10mg powder (Bedford), Dexrazoxane 250mg (Bedford), A-Methapred 125mg 2ml uni-vial 10/bx (Hospira) and  Elspar (Ovation).  We are making every effort to make sure our customers Leucovorin Calcium needs are met.  Bedford Labs has had two releases of Leucovorin 350mg powder in the last month, which has allowed us to temporarily remove the product from allocation only status at this time.

 

Did you know that drug shortages are listed on the FDA website and can be found at this address

http://www.fda.gov/Drugs/DrugSafety/DrugShortages/? Take a moment to sign up for email notifications while you are visiting the site.  The site is updated frequently and automatically sends email notifications of shortages and resolved shortages.  Current market shortages that are affecting our market are  Mitomycin, Leucovorin, Etoposide,  Bleomycin, Furosemide, Heparin, Cisplatin, and Propofol.

 

Upcoming FDA approval is anticipated for Sodium Ferric Gluconate a generic for Ferrlecit (Sanofi). Stay tuned.

 

 Sharon Gilbow

 Purchasing Manager
 
Use this area to provide your subscribers information about your organization.
 
Sincerely,
 

Kim Schultz
Florida Infusion